Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans
Dianthus Therapeutics (NASDAQ: DNTH) outlined its pipeline plans and competitive advantages at a recent Biotech Summit, with a key focus on its lead complement inhibitor program. The company expects an interim readout from its Phase 3 CIDP trial in Q2 2026 and aims to expand indications for DNTH212 and advance its MG program. Dianthus finished 2025 with $514 million, providing a cash runway into 2028.
DNTH: Key 2026 clinical milestones and strong commercial outlook drive optimism for pipeline success
Dianthus Therapeutics (DNTH) is anticipated to achieve significant clinical milestones in 2026 for CIDP, MMN, and DNTH212, with a strong competitive position based on efficacy and safety. The company holds a robust cash position, expected to extend into 2028, which underpins its substantial commercial potential. This optimistic outlook is based on a Guggenheim Securities Biotech Summit audio transcript.
Wedbush Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $55.00
Wedbush has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) from $46.00 to $55.00, maintaining an "outperform" rating, while other analysts also show bullish sentiment with a consensus "Moderate Buy" rating and an average target of $67.63. Despite some insider selling, institutional investors have been modifying their holdings in the company. Dianthus Therapeutics, a clinical-stage biotechnology company, is developing DNTH103 for severe autoimmune and inflammatory diseases.
Candriam S.C.A. Purchases 60,852 Shares of Dianthus Therapeutics, Inc. $DNTH
Candriam S.C.A. increased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 25.3% in the third quarter, acquiring 60,852 shares to hold a total of 301,428 shares valued at $11.86 million. This increase in institutional ownership comes despite significant insider selling, where executives sold 216,538 shares worth approximately $8.28 million. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $66.50.
How Investors Are Reacting To Dianthus Therapeutics (DNTH) US$600 Million Universal Shelf Registration
Dianthus Therapeutics (DNTH) recently filed a US$600 million universal shelf registration, providing flexibility for future capital raises but also raising concerns about potential shareholder dilution. The clinical-stage biotech is focused on its complement and immunology pipeline, with investors monitoring Phase 2 data and execution risks. Despite a fair value estimate that suggests the stock may be overvalued, the company's participation in a biotech summit aims to enhance visibility.
Assessing Dianthus Therapeutics (DNTH) Valuation After New US$600m Shelf Registration Filing
Dianthus Therapeutics (DNTH) recently filed a US$600 million universal shelf registration, providing flexibility for future capital access. The stock has seen significant momentum, with a 1-year return of over 120%, and its P/B ratio of 4x is below peers but above the broader US biotech industry, suggesting a nuanced valuation. Investors should consider the potential for dilution and clinical trial outcomes when assessing the company's future.
Dianthus CEO joins analyst-led fireside chat at Guggenheim summit
Dianthus Therapeutics (NASDAQ: DNTH) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, with CEO Marino Garcia joining an analyst-led fireside chat and investor meetings on February 12, 2026. The company recently filed an S-3 shelf registration for up to $600 million and holds significant cash reserves of $514-$525 million. Despite this, past stock reactions to similar news have been mixed, suggesting investors are looking for more definitive clinical readouts and financing decisions.
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Dianthus Therapeutics, a clinical-stage biotechnology company focused on severe autoimmune diseases, announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026. CEO Marino Garcia will engage in an analyst-led fireside chat and host one-on-one investor meetings on February 12, 2026. A webcast of the presentation will be available on the company's website.
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotechnology company, announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026. CEO Marino Garcia will engage in an analyst-led fireside chat and host one-on-one investor meetings on February 12, 2026, at 10:00 am EST. The company focuses on developing next-generation therapies for severe autoimmune diseases.
Dianthus Therapeutics (DNTH) Price Target Increased by 10.51% to 75.99
The average one-year price target for Dianthus Therapeutics (DNTH) has been increased by 10.51% to $75.99 per share, up from $68.77. This new target represents a 44.85% upside from the recent closing price of $52.46. The article also notes an increase in institutional ownership, with total shares held by institutions rising by 20.66% in the last three months, and various funds increasing their stakes in the company.
Dianthus Therapeutics (NASDAQ:DNTH) Given New $81.00 Price Target at Jefferies Financial Group
Jefferies Financial Group has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) from $66.00 to $81.00, reiterating a "buy" rating and suggesting a potential upside of over 52%. Despite this positive outlook, the company reported negative EPS and net margin, and insiders have sold off a significant number of shares recently. Analysts currently hold a "Moderate Buy" consensus rating with an average target price of $66.50 for the stock.
Dianthus Therapeutics stock hits 52-week high at 54.05 USD By Investing.com
Dianthus Therapeutics (DNTH) stock reached a new 52-week high of $54.05, representing a 144.6% increase over the past year and a 136.09% return in the last six months, with a market capitalization of $2.29 billion. This surge is driven by strong investor confidence, positive analyst recommendations, and recent developments including raised price targets from Oppenheimer and H.C. Wainwright, and the initiation of a Phase 1 clinical trial for LBL-047 (DNTH212). Despite being considered slightly overvalued by InvestingPro's Fair Value model, the company maintains strong financial health, though profitability is not expected this year.
Dianthus Therapeutics stock hits 52-week high at 54.05 USD By Investing.com
Dianthus Therapeutics (DNTH) stock has reached a new 52-week high of $54.05, driven by strong performance, investor confidence, and a 144.6% increase in its stock price over the past year. Despite being considered slightly overvalued by InvestingPro's Fair Value model, analysts maintain a "Strong Buy" rating with a target of $100. The company has upcoming earnings, along with recent positive developments including raised price targets from Oppenheimer and H.C. Wainwright, and the initiation of a Phase 1 clinical trial for LBL-047 (DNTH212).
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week High - Should You Buy?
Dianthus Therapeutics (NASDAQ:DNTH) recently hit a new 52-week high, trading at $54.52, with a market capitalization of $2.29 billion. Analyst sentiment is a "Moderate Buy" with a consensus price target of $64.43, yet the company reported a quarterly loss and negative margins. Insider selling was noted last quarter, though institutional investors like Vanguard and UBS increased their stakes.
Dianthus Therapeutics stock hits 52-week high at 54.05 USD By Investing.com
Dianthus Therapeutics (DNTH) stock recently reached a new 52-week high of $54.05, reflecting a remarkable 144.6% increase over the past year and a 136.09% return in the last six months. Despite being slightly overvalued according to InvestingPro's Fair Value model, analysts maintain a "Strong Buy" consensus with a high price target of $100, driven by the company's strong financial health and recent positive developments in clinical trials. Oppenheimer and H.C. Wainwright have both raised their price targets for DNTH, following encouraging Phase 2 trial data for claseprubart and the initiation of a Phase 1 trial for LBL-047 in systemic lupus erythematosus.
Dianthus Therapeutics stock hits 52-week high at 54.05 USD
Dianthus Therapeutics (DNTH) stock reached a 52-week high of $54.05, marking a 144.6% increase over the past year and a 136.09% return in the last six months, with its market capitalization now at $2.29 billion. Despite the stock appearing slightly overvalued by InvestingPro's Fair Value model, analysts maintain a "Strong Buy" recommendation with a high price target of $100. The company shows strong financial health with more cash than debt, though profitability is not expected this year.
Oppenheimer raises Dianthus Therapeutics stock price target to $125 from $62
Oppenheimer has significantly raised its price target for Dianthus Therapeutics (NASDAQ:DNTH) from $62.00 to $125.00, while maintaining an Outperform rating. This increase reflects the company's strong year-to-date performance, including a 142% total return over the past year, and anticipated positive catalysts such as upcoming data releases for its drug candidates. The firm believes the stock is in early stages of appreciation as investors gain confidence in its product profiles.
Oppenheimer Boosts Price Target on Dianthus Therapeutics to $125 From $62, Keeps Outperform Rating
Oppenheimer has significantly increased its price target for Dianthus Therapeutics (DNTH) to $125 from $62, while maintaining an Outperform rating. This adjustment reflects a strong positive outlook on the biopharmaceutical company, which specializes in advancing antibody complement therapeutics for severe autoimmune diseases. The report was issued on January 29, 2026, according to MT Newswires.
Dianthus Therapeutics May Issue Up To $600 Million In Securities
Dianthus Therapeutics (DNTH) has announced that it may issue up to $600 million in various securities. This information was reported by Refinitiv and suggests a potential capital-raising initiative for the company. The news is brief and published by Reuters.
Dianthus Therapeutics (DNTH) Is Up 18.7% After Claseprubart Trial Progress Reshapes Its Autoimmune Focus
Dianthus Therapeutics (DNTH) saw its stock rise 18.7% following positive developments in its clinical trials for claseprubart, targeting autoimmune neuromuscular conditions, and DNTH212 for systemic lupus erythematosus. The company's investment narrative is closely tied to the success of its complement-focused pipeline, with recent share price movements reflecting investor enthusiasm for these clinical milestones despite current modest revenues and ongoing losses. While potential dilution and execution risks remain, analysts are optimistic about the long-term prospects.
Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last?
Dianthus Therapeutics (DNTH) saw its shares jump 9.9% following positive investor sentiment regarding its clinical-stage pipeline candidates, claseprubart and DNTH212, for autoimmune conditions. Despite this gain, the company is projected to report a quarterly loss and decreased revenues. Investors are advised to monitor trends in earnings estimate revisions to determine if the stock's recent strength will be sustained.
Dianthus Therapeutics stock hits 52-week high at 46.6 USD By Investing.com
Dianthus Therapeutics (DNTH) stock has reached a new 52-week high of $46.6, marking a 120.5% increase over the past year and a 116.18% gain in the last six months. This surge reflects strong investor confidence despite analysis suggesting the stock might be trading above its Fair Value, and the company has a market capitalization of nearly $2 billion. Recent positive developments include the initiation of a Phase 1 clinical trial for LBL-047 (DNTH212) targeting autoimmune disorders and H.C. Wainwright raising its price target to $47.00 following encouraging Phase 2 data for claseprubart in myasthenia gravis.
Dianthus Therapeutics stock hits 52-week high at 46.6 USD By Investing.com
Dianthus Therapeutics (DNTH) stock has reached a new 52-week high of $46.6, marking a 120.5% increase over the past year and a 116.18% gain in six months. This surge reflects strong investor confidence despite analyses suggesting it might be trading above its Fair Value. The company is advancing its therapeutic portfolio, including a Phase 1 clinical trial for LBL-047 (DNTH212) for autoimmune disorders and positive Phase 2 data for claseprubart in myasthenia gravis, leading analysts like H.C. Wainwright to raise price targets.
Dianthus Therapeutics stock hits 52-week high at 46.6 USD By Investing.com
Dianthus Therapeutics Inc. (DNTH) stock reached a 52-week high of $46.6 USD, marking a 120.5% increase over the past year and a 116.18% gain in the last six months. The biopharmaceutical company, with a market capitalization of nearly $2 billion, shows strong investor confidence, despite being potentially overvalued according to InvestingPro. Recent positive developments include the initiation of a Phase 1 clinical trial for LBL-047 (DNTH212) targeting autoimmune disorders and an increased price target from H.C. Wainwright following positive Phase 2 data for claseprubart in myasthenia gravis.
Dianthus Therapeutics stock hits 52-week high at 46.6 USD
Dianthus Therapeutics Inc (DNTH) stock reached a new 52-week high of $46.6, marking a 120.5% increase over the past year and a 116.18% gain in six months, with a market capitalization of nearly $2 billion. This surge reflects investor confidence, despite an InvestingPro analysis suggesting the stock might be trading above its Fair Value. The company is advancing its therapeutic offerings, including a Phase 1 clinical trial for LBL-047 (DNTH212) targeting autoimmune disorders and positive Phase 2 trial data for claseprubart in myasthenia gravis, leading H.C. Wainwright to raise its price target to $47.00.
Dianthus Therapeutics stock hits 52-week high at 46.6 USD By Investing.com
Dianthus Therapeutics (DNTH) stock has reached a new 52-week high of $46.60, marking a 120.5% increase over the past year and a 116.18% gain in six months. This surge reflects strong investor confidence despite some analyses suggesting the stock may be trading above its Fair Value. The company recently commenced a Phase 1 clinical trial for LBL-047 (DNTH212) targeting autoimmune disorders and received a raised price target from H.C. Wainwright to $47.00 after positive Phase 2 data for claseprubart.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 47.4% in December
Dianthus Therapeutics (NASDAQ:DNTH) experienced a significant increase in short interest in December, rising by 47.4% to 6,136,786 shares, representing about 17.2% of its shares short. Despite recent insider selling totaling over $8 million and an earnings miss, analysts maintain a "Moderate Buy" rating with an average target price of $64.43, significantly higher than its current trading price of around $44.10. The company's stock has shown recent price appreciation, with its 50-day moving average at $41.43 and 200-day at $32.70.
First Week of March 20th Options Trading For Dianthus Therapeutics (DNTH)
New options contracts for Dianthus Therapeutics (DNTH) for the March 20th expiration have begun trading. The article identifies a put contract at a $40.00 strike price offering a potential 2.75% return (15.94% annualized) if it expires worthless, and a call contract at a $45.00 strike price, which could yield an 8.08% total return if the stock is called away. Analysis suggests probabilities for both contracts to expire worthless, offering different investment strategies.
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1% - Should You Sell?
Dianthus Therapeutics (NASDAQ:DNTH) experienced a 6.1% drop in its stock price, trading at around $43.48 with significantly reduced volume. Despite a "Moderate Buy" consensus from analysts with a target price of $64.43, the company missed its quarterly EPS estimates and reported low revenue, accompanied by substantial insider selling. This mixed sentiment suggests caution for investors considering the stock.
Dianthus Therapeutics stock hits 52-week high at $45.56
Dianthus Therapeutics Inc. (DNTH) stock has reached a new 52-week high of $45.56, with a 1-year return of 69.79% and a 6-month return of 95.01%. This upward trend is supported by the company's strong financial position and recent positive developments, including the dosing of the first subject in a Phase 1 clinical trial for LBL-047 and raised price targets from analysts following promising Phase 2 data for claseprubart. Despite appearing overvalued by some metrics, analysts maintain Buy ratings, citing the potential of its strategic moves and research in autoimmune disorders.
Dianthus Therapeutics stock hits 52-week high at $45.56 By Investing.com
Dianthus Therapeutics Inc. (DNTH) stock hit a new 52-week high of $45.56, with a current trading price of $45.70, reflecting significant growth over the past year and six months. The company's strong financial position, with more cash than debt and exceeding short-term obligations, supports this upward trajectory in the biotechnology market. Analysts have set price targets between $46 and $100, and recent developments like the dosing of LBL-047 in a Phase 1 trial and positive data for claseprubart have further boosted investor confidence.
Dianthus Therapeutics stock hits 52-week high at $45.56 By Investing.com
Dianthus Therapeutics Inc. stock has reached a new 52-week high of $45.56, with a significant surge of 69.79% over the past year and 95.01% in the last six months. The company has a market capitalization of $1.88 billion and analysts have set price targets between $46 and $100. Recent news includes the dosing of the first subject for their Phase 1 clinical trial of LBL-047 (DNTH212) and increased price targets from H.C. Wainwright, Oppenheimer, TD Cowen, and Guggenheim due to positive clinical data and licensing agreements.
Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $63.00
Truist Financial has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) from $56.00 to $63.00, reiterating a "buy" rating and implying a potential upside of nearly 64%. Despite this optimistic outlook and a consensus target price of $64.43 from analysts, the company remains unprofitable, missing its last quarterly EPS estimate. Insider activity shows significant selling of shares by executives in the last quarter.
Biotech targeting severe autoimmune diseases to present at JPM event
Dianthus Therapeutics (Nasdaq: DNTH) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, where CEO Marino Garcia will present a corporate overview and hold investor meetings. The announcement led to a 7.03% decline in DNTH stock, reflecting a negative market reaction despite the neutral nature of such conference participations. The company aims to highlight its pipeline of therapies for severe autoimmune diseases and engage with investors.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Analysts
Nine analysts have given Dianthus Therapeutics, Inc. (NASDAQ:DNTH) a "Moderate Buy" consensus rating, with an average 1-year price target of $63.43. This optimism comes despite recent weak quarterly results and significant insider selling totaling over $8.28 million by executives. Institutional investors have been increasing their stakes, while the stock currently trades near $36.89 with a market cap around $1.58 billion.
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. CEO Marino Garcia will present a corporate overview and host one-on-one meetings with investors on January 12, 2026. A webcast of the presentation will be available on the company's website.
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) announced its participation in the 44th Annual J.P. Morgan Healthcare conference. CEO Marino Garcia will present a corporate overview and host one-on-one meetings with investors on January 12, 2026. The presentation will also be webcast on the company's website.
New lupus drug test begins, aiming for simple self-injections every month
Dianthus Therapeutics (Nasdaq: DNTH) and Leads Biolabs have initiated a Phase 1 clinical trial for LBL-047 (DNTH212), a bifunctional fusion protein targeting BDCA2 and BAFF/APRIL to treat systemic lupus erythematosus (SLE) and other autoimmune diseases. The trial will evaluate safety, tolerability, and PK/PD in healthy volunteers and SLE patients, with top-line healthy-volunteer results expected in the second half of 2026. This development stems from an exclusive global partnership with a potential value of up to $1 billion, aiming for a patient-friendly, less frequent subcutaneous self-administration regimen.
Leads Biolabs and Dianthus Therapeutics Initiate Phase 1 Trial for LBL-047 (DNTH212), a Bifunctional Fusion Protein Targeting Autoimmune Disorders
Leads Biolabs and Dianthus Therapeutics have begun a Phase 1 clinical trial for LBL-047 (DNTH212), a bifunctional fusion protein aimed at treating autoimmune disorders by reducing Type 1 interferon production and inhibiting B cell function. This trial will evaluate the drug's safety and pharmacokinetics in healthy volunteers and systemic lupus erythematosus patients. LBL-047 is designed for patient-friendly self-administration every four weeks or less, with Dianthus expected to announce prioritized indications in early 2026.
Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus
Leads Biolabs and Dianthus Therapeutics have announced the initiation of a Phase 1 clinical trial for LBL-047 (DNTH212). This trial will involve both healthy volunteers and patients diagnosed with Systemic Lupus Erythematosus. The announcement was made through Reuters and specifies that the news item carries only a headline without further textual details.
First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH)
Dianthus Therapeutics Inc (DNTH) has new August 2026 options available, offering potential opportunities for investors due to the 245 days until expiration. The article details a put contract at a $40.00 strike price, which could result in a 16.25% return if it expires worthless, and a covered call contract at a $45.00 strike price, offering a potential 25.03% total return. These options provide strategies for both acquiring DNTH shares at a discount or generating income from existing holdings.
Bain Capital Life Sciences Investors LLC Has $46.24 Million Holdings in Dianthus Therapeutics, Inc. $DNTH
Bain Capital Life Sciences Investors LLC has reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 7.7%, now holding 2,482,250 shares valued at approximately $46.24 million. This represents 7.71% of DNTH and 5.8% of Bain Capital's portfolio. The article also notes significant insider selling, with 216,538 shares ($8.28 million) sold in the past 90 days, while analysts maintain a "Moderate Buy" rating with an average price target of $63.43 against a current trading price near $42.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Brokerages
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received an average rating of "Moderate Buy" from brokerages, with an average 12-month price target of $63.43. Despite this positive outlook, corporate insiders have sold a significant number of shares recently, and the company missed its latest quarterly EPS and revenue estimates. Institutional investors have notably increased their holdings in the company.
Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares
Dianthus Therapeutics CFO Ryan Savitz sold 20,000 shares of the company's stock on December 4th at an average price of $45.18, totaling $903,600. This follows a previous sale of 20,000 shares on September 9th for $700,000. Despite missing earnings estimates, with a quarterly EPS of ($0.97), and a negative net margin, Wall Street analysts maintain a largely positive outlook with a consensus "Moderate Buy" rating and a price target of $63.43.
Dianthus Therapeutics stock hits 52-week high at 45.0 USD By Investing.com
Dianthus Therapeutics Inc. (DNTH) reached a 52-week high of $45.0, reflecting a significant 86.81% 1-year change and 144.82% gain over six months, with analysts setting a high price target of $100. This milestone follows positive Phase 2 trial data for claseprubart and strategic licensing agreements, boosting investor confidence despite expectations of unprofitability this year.
27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd
XTX Topco Ltd initiated a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by purchasing 27,003 shares valued at approximately $503,000 during the second quarter. Despite significant institutional investment, company insiders have been net sellers, disposing of over 216,000 shares worth about $8.08 million in the past three months. Analysts maintain a "Moderate Buy" rating with an average target price of $63.43, even as the company faces negative earnings and margins.
Dianthus Therapeutics stock hits 52-week high at 45.0 USD
Dianthus Therapeutics Inc. (DNTH) stock has reached a 52-week high of 45.0 USD, reflecting an 86.81% 1-year change and strong investor confidence. The company shows significant returns over the past six months and year-to-date, with analysts maintaining high price targets and positive sentiment due to recent strategic developments and clinical advancements. Despite current unprofitability, Dianthus holds more cash than debt and continues to expand its therapeutic offerings.
Dianthus Therapeutics, Inc. $DNTH Shares Bought by Sio Capital Management LLC
Sio Capital Management LLC significantly increased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 101.8% in Q2, making it their 17th largest holding. Despite this institutional optimism and a "Moderate Buy" consensus from analysts with an average target price of $63.43, the company reported a quarterly miss and insiders have been net sellers. The article highlights a disconnect between bullish analyst ratings and current company performance and insider activity.
Ensign Peak Advisors Inc Invests $2.50 Million in Dianthus Therapeutics, Inc. $DNTH
Ensign Peak Advisors Inc has invested $2.50 million in Dianthus Therapeutics, Inc. by acquiring 134,416 shares, making it a new stakeholder with 0.42% ownership. Despite recent insider selling and negative earnings, analysts largely maintain a "Moderate Buy" rating with a consensus price target significantly above the current trading price. The company, a clinical-stage biotechnology firm, is developing treatments for severe autoimmune and inflammatory diseases.
Dianthus Therapeutics (Nasdaq: DNTH) joins 8th Evercore Healthcare Conference on Dec. 2
Dianthus Therapeutics (Nasdaq: DNTH) will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, in Coral Gables, Florida. CEO Marino Garcia will engage in a fireside chat and hold one-on-one investor meetings at the event. A live webcast of the presentation will be accessible via the Investors section of the company's website.
